tebapivat

all catalysts(0)

nothing on the calendar yet

News(8)

• Biotechs bring big launches and pharma rivalries into Q2 earnings period
  With the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.
  biospace · 22d ago
• Agios scraps sickle cell drug
  The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
  biopharma_dive · 1mo ago
• Agios’ second shot at sickle cell disease falls short
  Agios said it is dropping a next-generation sickle cell disease drug after lackluster results from a mid-stage trial. The drug, known as tebapivat, represented Agios’ second shot at the disease, an…
  endpoints · 1mo ago
• Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
  Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…
  biospace · 1mo ago
• STAT+: Anthropic deepens work with rare disease drugs
  Novo Nordisk sues Eli Lilly over GLP-1s, Medicare pricing plans, and more biotech news from The Readout
  stat · 1mo ago
• Agios says adios to sickle cell program over lackluster phase 2 data
  A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell disease, leading the company to ax an indication for t…
  fiercebiotech · 1mo ago
• Agios ends development of tebapivat in low-risk MDS following subpar results
  Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruv…
  endpoints · 2mo ago
• Allogene CEO to step down; Agios drug fails key test
  David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
  biopharma_dive · 2mo ago